Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Inozyme Pharma Inc shares valued at $7,849 were sold by Treco Douglas A on Apr 02 ’25. At $0.89 per share, Treco Douglas A sold 8,819 shares. The insider’s holdings dropped to 41,046 shares worth approximately $40225.08 following the completion of this transaction.
As published in their initiating research note from Raymond James on December 12, 2024, Inozyme Pharma Inc [INZY] has been an Outperform and the price target has been revised to $26. Analysts at Stifel started covering the stock with ‘”a Buy”‘ outlook in a report released in mid September. Earlier on May 30, 2024, Wells Fargo initiated its rating. Their recommendation was “an Overweight” for INZY stock.
Analyzing INZY Stock Performance
During the last five days, there has been a drop of approximately -1.66%. Over the course of the year, Inozyme Pharma Inc shares have dropped approximately -64.60%. Shares of the company reached a 52-week high of $3.1800 on 01/03/25 and a 52-week low of $0.7200 on 04/07/25. A 50-day SMA is recorded $1.0596, while a 200-day SMA reached $3.2786.
Support And Resistance Levels for Inozyme Pharma Inc (INZY)
According to the 24-hour chart, there is a support level at 0.9321, which, if violated, would cause prices to drop to 0.8837. In the upper region, resistance lies at 1.0542. The next price resistance is at 1.1279. RSI (Relative Strength Index) is 49.53 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.0705, which suggests the price will decrease in the coming days. Percent R is at 27.61%, indicating bullish price movement. Stochastics %K at holding indicates that the stock is to be held.
